Determination of p-trifluoromethylphenol, a metabolite of fluoxetine, in tissues and body fluids using an electron-capture gas chromatographic procedure

被引:16
作者
Urichuk, LJ [1 ]
Aspeslet, LJ [1 ]
Holt, A [1 ]
Silverstone, PH [1 ]
Coutts, RT [1 ]
Baker, GB [1 ]
机构
[1] UNIV ALBERTA,DEPT PSYCHIAT,NEUROCHEM RES UNIT,EDMONTON,AB T6G 2B7,CANADA
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 698卷 / 1-2期
关键词
p-trifluoromethylphenol; fluoxetine; pentafluorobenzenesulfonyl chloride;
D O I
10.1016/S0378-4347(97)00304-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An electron-capture gas chromatographic procedure was developed for the analysis of p-trifluoromethylphenol, an O-dealkylated metabolite of fluoxetine, in biological samples. A basic extraction of the biological sample was employed, followed by derivatization with pentafluorobenzenesulfonyl chloride. The internal standard, 2,4-dichlorophenol, was added to all samples used in the procedure to aid in quantitation. The practical limit of detection (signal-to-noise ratio>3) for p-trifluoromethylphenol was <5 ng/ml in human plasma samples, <10 ng/g of rat brain tissue, <25 ng/g of rat liver tissue and <25 ng/ml in human and rat urine samples. In the rat, the levels of free p-trifluoromethylphenol in the liver were 10-fold higher than those in the brain, and a substantial amount was excreted in the urine. Human urine samples contained levels of free p-trifluoromethylphenol approximately 30-fold higher than those found in human plasma samples. The procedure described is useful for the detection and quantitation of free p-trifluoromethylphenol in humans and rats treated with fluoxetine. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 18 条
[1]   CLINICAL PHARMACOKINETICS OF FLUOXETINE [J].
ALTAMURA, AC ;
MORO, AR ;
PERCUDANI, M .
CLINICAL PHARMACOKINETICS, 1994, 26 (03) :201-214
[2]  
BAKER GB, 1986, RES COMMUN CHEM PATH, V54, P141
[3]   ELECTRON-CAPTURE GAS-CHROMATOGRAPHIC ANALYSIS OF BETA-PHENYLETHYLAMINE IN TISSUES AND BODY-FLUIDS USING PENTAFLUOROBENZENESULFONYL CHLORIDE FOR DERIVATIZATION [J].
BAKER, GB ;
RAO, TS ;
COUTTS, RT .
JOURNAL OF CHROMATOGRAPHY, 1986, 381 (02) :211-217
[4]  
BAKER GB, 1986, P W PHARMACOL SOC, V29, P291
[5]   FLUOXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
HEEL, RC ;
LEWIS, SP .
DRUGS, 1986, 32 (06) :481-508
[6]   CLINICAL-PHARMACOLOGY AND PHARMACOKINETICS OF FLUOXETINE - A REVIEW [J].
BERGSTROM, RF ;
LEMBERGER, L ;
FARID, NA ;
WOLEN, RL .
BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 :47-50
[7]   FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
SKJELBO, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :136-137
[8]   INFLUENCE OF DOSE AND ROUTE OF ADMINISTRATION ON THE KINETICS OF FLUOXETINE AND ITS METABOLITE NORFLUOXETINE IN THE RAT [J].
CACCIA, S ;
CAPPI, M ;
FRACASSO, C ;
GARATTINI, S .
PSYCHOPHARMACOLOGY, 1990, 100 (04) :509-514
[9]  
CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P213
[10]  
COUTTS RT, 1994, J PSYCHIATR NEUROSCI, V19, P30